4/13/2020
`
`CM/ECF for JPML (LIVE)
`
`TRANSFERRED
`
`United States Judicial Panel on Multidistrict Litigation
`CIVIL DOCKET FOR CASE #: MDL No. 2902
`
`IN RE: Sitagliptin Phosphate ('708 & '921) Patent Litigation
`Assigned to: Richard G. Andrews
`Transferee District: Delaware
`Master Docket Number: 1:19-md-2902
`Plaintiff
`Liaison Counsel for Plaintiffs
`
`Date Filed: 05/15/2019
`MDL Status: Transferred
`Date Ordered: 08/08/2019
`Citation: 402 F.Supp.3d No. 1366
`
`V.
`Defendant
`Liaison Counsel for Defendants
`
`Date Filed
`05/15/2019
`
`05/16/2019
`
`05/16/2019
`
`# Docket Text
`1 MOTION TO TRANSFER (INITIAL MOTION) with Brief in Support. -- 14 Action(s) --
`from West Virginia Northern District Court (1:19-cv-00101), District of Delaware (1:19-
`310, 1:19-311, 1:19-312, 1:19-313; 1:19-314; 1:19-316; 1:19-317; 1:19-318; 1:19-319,
`1:19-320, 1:19-321; 1:19-347; 1:19-872) - Suggested Transferee Court: D. Del. - Filed by:
`Plaintiff Merck Sharp & Dohme Corp. (Attachments: # 1 Memorandum, # 2 Schedule of
`Actions, # 3 Proof of Service, # 4 Complaint DE 19-0310, # 5 Complaint DE 19-0311, # 6
`Complaint DE 19-0312, # 7 Complaint DE 19-0313, # 8 Complaint DE 19-0314, # 9
`Complaint DE 19-0316, # 10 Complaint DE 19-0317, # 11 Complaint DE 19-0318, # 12
`Complaint DE 19-0319, # 13 Complaint DE 19-0320, # 14 Complaint DE 19-0321, # 15
`Complaint DE 19-0347, # 16 Complaint DE 19-0872, # 17 Complaint WVN 19-0101)
`(Sheh, Anthony) Modified on 5/16/2019 (TB). CHANGED NUMBER OF ACTIONS
`FROM 1 TO 14; ADDED ADDITIONAL 13 ACTIONS INTO SYSTEM AND DOCKET
`TEXT. (Entered: 05/15/2019)
`2 MDL Number 2902 Assigned -- MOTION FOR TRANSFER ACCEPTED FOR FILING
`re: pldg. ( 1 in Pending No. 31) Associated Cases: Pending No. 31, DE/1:19-cv-00310,
`DE/1:19-cv-00311, DE/1:19-cv-00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-
`cv-00316, DE/1:19-cv-00317, DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320,
`DE/1:19-cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (TB)
`(Entered: 05/16/2019)
`3 ***TEXT ONLY NOTICE***
`
`NOTICE OF FILING AND PUBLICATION OF BRIEFING SCHEDULE re: pldg. (
`1 in MDL No. 2902)
`
`BRIEFING SCHEDULE IS SET AS FOLLOWS:
`Notices of Appearance due on or before 5/30/2019. Corporate Disclosure Statements
`due on or before 5/30/2019. Responses due on or before 6/6/2019.
`Reply, if any, due on or before 6/13/2019.
`
`https://ecf.jpml.uscourts.gov/cgi-bin/DktRpt.pl?46647738864669-L_1_0-1
`
`1/9
`
`Merck Sharp & Dohme Corp. Exhibit 2021
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040 Page 1
`
`

`

`4/13/2020
`
`05/23/2019
`
`05/23/2019
`
`05/29/2019
`
`05/29/2019
`
`05/29/2019
`
`05/29/2019
`
`05/29/2019
`
`CM/ECF for JPML (LIVE)
`In their briefs, the parties should address what steps they have taken to pursue
`alternatives to centralization (including, but not limited to, engaging in informal
`coordination of discovery and scheduling, and seeking Section 1404 transfer of one or
`more of the subject cases).
`
`Appearance forms (JPML form 18) and Corporate Disclosure forms can be downloaded
`from our website. Important: A Corporate Disclosure Form, if required, must be filed,
`even if one has previously been filed in this MDL.
`
`Please visit the CM/ECF Filing Guidelines & Forms page of our website for additional
`information.
`
`Signed by Clerk of the Panel John W. Nichols on 5/16/2019.
`
`Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-
`00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317,
`DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-
`cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (TB) (Entered: 05/16/2019)
`4 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by William R
`Zimmerman on behalf of Defendant Lupin Pharmaceuticals, Inc. and Lupin Limited
`Associated Cases: MDL No. 2902, DE/1:19-cv-00347 (Zimmerman, William) Modified
`on 5/23/2019 (SM).ADDED PARTY NAME (Entered: 05/23/2019)
`5 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent LUPIN LIMITED for Lupin Pharmaceuticals, Inc..
`Associated Cases: MDL No. 2902, DE/1:19-cv-00347 (Zimmerman, William) (Entered:
`05/23/2019)
`6 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by David Abramowitz
`on behalf of Defendants Cadila Healthcare Ltd., et al. Associated Cases: MDL No. 2902,
`DE/1:19-cv-00314 (Abramowitz, David) (Entered: 05/29/2019)
`7 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by Anthony H. Sheh on
`behalf of Plaintiff Merck Sharp & Dohme Corp. (Attachments: # 1 Exhibit A, # 2 Proof of
`Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311,
`DE/1:19-cv-00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-
`cv-00317, DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321,
`DE/1:19-cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (Sheh, Anthony) (Entered:
`05/29/2019)
`8 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent MERCK & CO., INC. for Merck Sharp & Dohme Corp..
`(Attachments: # 1 Exhibit A, # 2 Proof of Service) Associated Cases: MDL No. 2902,
`DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00312, DE/1:19-cv-00313, DE/1:19-
`cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317, DE/1:19-cv-00318, DE/1:19-cv-00319,
`DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872,
`WVN/1:19-cv-00101 (Sheh, Anthony) (Entered: 05/29/2019)
`9 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent No Parent Corp. for Cadila Healthcare Ltd.; Corporate
`Parent Cadila Healthcare Limited for Zydus Pharmaceuticals (USA), Inc.. (Attachments:
`# 1 Other Schedule A, # 2 Other Schedule B) Associated Cases: MDL No. 2902, DE/1:19-
`cv-00314 (Abramowitz, David) (Entered: 05/29/2019)
`10 CERTIFICATE OF SERVICE re: pldg. (3 in DE/1:19-cv-00314, 6 in MDL No. 2902), (6
`in DE/1:19-cv-00314, 9 in MDL No. 2902) Filed by Defendants Cadila Healthcare Ltd., et
`
`https://ecf.jpml.uscourts.gov/cgi-bin/DktRpt.pl?46647738864669-L_1_0-1
`
`2/9
`
`Merck Sharp & Dohme Corp. Exhibit 2021
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040 Page 2
`
`

`

`4/13/2020
`
`05/30/2019
`
`CM/ECF for JPML (LIVE)
`al. -- Associated Cases: MDL No. 2902, DE/1:19-cv-00314 (Abramowitz, David)
`(Entered: 05/29/2019)
`11 FILED IN ERROR SEE CORRECTED PLEADING NO. 25
`
`NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by Charles B Klein on
`behalf of Defendants Sun Pharma Global FZE,
`
`05/30/2019
`
`et al. (Klein, Charles) Modified on 5/31/2019 (DP). (Entered: 05/30/2019)
`12 FILED IN ERROR SEE CORRECTED PLEADING NO. 26
`
`05/30/2019
`
`CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Other Affiliate None for Sun Pharmaceutical Industries Ltd.; Corporate
`Parent Sun Pharmaceutical Industries Ltd for Sun Pharma Global FZE. (Klein, Charles)
`Modified on 5/31/2019 (DP). (Entered: 05/30/2019)
`13 FILED IN ERROR SEE CORRECTED PLEADING NO. 30
`
`CERTIFICATE OF SERVICE re: pldg. ( 12 in MDL No. 2902), ( 11 in MDL No. 2902)
`Filed by Defendants Sun Pharma Global FZE,
`
`05/30/2019
`
`et al. -- (Klein, Charles) Modified on 5/31/2019 (DP). (Entered: 05/30/2019)
`14 FILED IN ERROR SEE CORRECTED PLEADING NO. 30
`
`CERTIFICATE OF SERVICE re: pldg. ( 12 in MDL No. 2902), ( 11 in MDL No. 2902)
`Filed by Defendants Sun Pharma Global FZE,
`
`et al. -- (Klein, Charles) Modified on 5/31/2019 (DP). (Entered: 05/30/2019)
`15 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by Dominick Gattuso
`on behalf Keith Zullow for Defendant Watson Laboratories, Inc. Associated Cases: MDL
`No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00313, DE/1:19-cv-00314,
`DE/1:19-cv-00316, DE/1:19-cv-00317, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-
`cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (Gattuso,
`Dominick) Modified on 6/14/2019 (DP)(EDITED DOCKET ENTRY). (Entered:
`05/30/2019)
`16 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by Dominick Gattuso
`on behalf Keith Zullow for Defendant Teva Pharmaceuticals USA, Inc. Associated Cases:
`MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00313, DE/1:19-cv-
`00314, DE/1:19-cv-00316, DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320,
`DE/1:19-cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (Gattuso,
`Dominick) Modified on 6/14/2019 (DP)(EDITED DOCKET ENTRY). (Entered:
`05/30/2019)
`17 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by Dominick Gattuso
`on behalf Keith Zullow for Defendant Sandoz Inc. Associated Cases: MDL No. 2902,
`DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00312, DE/1:19-cv-00313, DE/1:19-
`cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321,
`DE/1:19-cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (Gattuso, Dominick)
`Modified on 6/14/2019 (DP)(EDITED DOCKET ENTRY). (Entered: 05/30/2019)
`18 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by Neal Seth on behalf
`of Defendants Torrent Pharma Inc., et al. (Attachments: # 1 Other Attachment A, # 2 Other
`Attachment B, # 3 Proof of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`https://ecf.jpml.uscourts.gov/cgi-bin/DktRpt.pl?46647738864669-L_1_0-1
`
`3/9
`
`Merck Sharp & Dohme Corp. Exhibit 2021
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040 Page 3
`
`

`

`4/13/2020
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`CM/ECF for JPML (LIVE)
`00316, DE/1:19-cv-00320, DE/1:19-cv-00872 (Seth, Neal) Modified on 5/30/2019 (DP)
`(REMOVED DUPLICATE PARTY NAMES). (Entered: 05/30/2019)
`19 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent Novartis AG for Sandoz Inc.. (Attachments: # 1 Exhibit
`Certificate of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-
`00311, DE/1:19-cv-00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316,
`DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-cv-00347, DE/1:19-
`cv-00872 (Gattuso, Dominick) (Entered: 05/30/2019)
`20 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent Teva Pharmaceutical Industries Ltd., for Teva
`Pharmaceuticals USA, Inc.. (Attachments: # 1 Exhibit Certificate of Service) Associated
`Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00313,
`DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-
`cv-00320, DE/1:19-cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872 (Gattuso, Dominick)
`(Entered: 05/30/2019)
`21 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent No Parent Corp for Macleods Pharmaceuticals Limited;
`Corporate Parent Macleods Pharmaceuticals Limited for Macleods Pharma USA, Inc..
`(Attachments: # 1 Other Attachment A, # 2 Other Attachment B, # 3 Proof of Service)
`Associated Cases: MDL No. 2902, DE/1:19-cv-00316 (Seth, Neal) (Entered: 05/30/2019)
`22 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent TEVA PHARMACEUTICALS USA, INC., Corporate
`Parent Teva Pharmaceutical Industries Ltd., for Watson Laboratories, Inc.. (Attachments:
`# 1 Exhibit Certificate of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00310,
`DE/1:19-cv-00311, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-
`cv-00317, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-cv-00347,
`DE/1:19-cv-00872, WVN/1:19-cv-00101 (Gattuso, Dominick) (Entered: 05/30/2019)
`23 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent Torrent Pharmaceuticals Ltd. for Torrent Pharma Inc.;
`Corporate Parent TORRENT PRIVATE LIMITED for Torrent Pharmaceuticals Limited.
`(Attachments: # 1 Other Attachment A, # 2 Other Attachment B, # 3 Other Attachment C,
`# 4 Proof of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00320, DE/1:19-cv-
`00872 (Seth, Neal) (Entered: 05/30/2019)
`24 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by Gordon H. Copland
`on behalf of Defendants Mylan Inc., Mylan Pharmaceuticals Inc. (Attachments: # 1
`Exhibit Party list, # 2 Proof of Service) Associated Cases: MDL No. 2902, WVN/1:19-cv-
`00101 (Copland, Gordon) (Entered: 05/30/2019)
`25 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by Charles B Klein on
`behalf of Defendants Sun Pharma Global FZE, et al. Associated Cases: MDL No. 2902,
`DE/1:19-cv-00319 (Klein, Charles) (Entered: 05/30/2019)
`26 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent No Parent Corporation for Sun Pharmaceutical Industries
`Ltd.; Corporate Parent Sun Pharmaceutical Industries Ltd for Sun Pharma Global FZE.
`Associated Cases: MDL No. 2902, DE/1:19-cv-00319 (Klein, Charles) (Entered:
`05/30/2019)
`27 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent MYLAN INC., Corporate Parent Mylan N. V. for Mylan
`Pharmaceuticals Inc.. (Attachments: # 1 Exhibit Listing of corp. affiliations, # 2 Proof of
`
`https://ecf.jpml.uscourts.gov/cgi-bin/DktRpt.pl?46647738864669-L_1_0-1
`
`4/9
`
`Merck Sharp & Dohme Corp. Exhibit 2021
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040 Page 4
`
`

`

`4/13/2020
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/30/2019
`
`05/31/2019
`
`05/31/2019
`
`05/31/2019
`
`CM/ECF for JPML (LIVE)
`Service) Associated Cases: MDL No. 2902, WVN/1:19-cv-00101 (Copland, Gordon)
`(Entered: 05/30/2019)
`28 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by Matthew J. Becker
`on behalf of Defendants Alvogen Malta Operations Ltd., Alvogen Pine Brook LLC
`(Attachments: # 1 Proof of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00310
`(Becker, Matthew) (Entered: 05/30/2019)
`29 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent Alvogen Lux Holdings S.a.r.l. for Alvogen Malta
`Operations Ltd.; Corporate Parent Alvogen Malta Operations Ltd. for Alvogen Pine
`Brook LLC. (Attachments: # 1 Proof of Service) Associated Cases: MDL No. 2902,
`DE/1:19-cv-00310 (Becker, Matthew) (Entered: 05/30/2019)
`30 CERTIFICATE OF SERVICE re: pldg. (12 in DE/1:19-cv-00319, 26 in MDL No. 2902),
`(11 in DE/1:19-cv-00319, 25 in MDL No. 2902) Filed by Defendants Sun Pharma Global
`FZE, et al. -- Associated Cases: MDL No. 2902, DE/1:19-cv-00319 (Klein, Charles)
`(Entered: 05/30/2019)
`31 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by David H. Silverstein
`on behalf of Defendants Anchen Pharmaceuticals, Inc., et al. (Attachments: # 1 Schedule
`of Actions, # 2 Proof of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00311,
`DE/1:19-cv-00321 (Silverstein, David) (Entered: 05/30/2019)
`32 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent Endo International PLC for Par Pharmaceuticals, Inc..
`(Attachments: # 1 Proof of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00311
`(Silverstein, David) (Entered: 05/30/2019)
`33 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent PAR Pharmaceutical, Inc., Corporate Parent Endo
`International PLC for Anchen Pharmaceuticals, Inc.. (Attachments: # 1 Proof of Service)
`Associated Cases: MDL No. 2902, DE/1:19-cv-00311 (Silverstein, David) (Entered:
`05/30/2019)
`34 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent Wockhardt Ltd. for Wockhardt Bio AG, Wockhardt USA
`LLC. (Attachments: # 1 Proof of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-
`00321 (Silverstein, David) (Entered: 05/30/2019)
`35 CERTIFICATE OF SERVICE re: pldg. ( 15 in MDL No. 2902, 5 in DE/1:19-cv-00872)
`Filed by Defendant Watson Laboratories, Inc. -- Associated Cases: MDL No. 2902,
`DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-
`cv-00316, DE/1:19-cv-00317, DE/1:19-cv-00319, DE/1:19-cv-00321, DE/1:19-cv-00347,
`DE/1:19-cv-00872, WVN/1:19-cv-00101 (Gattuso, Dominick) Modified on 6/3/2019 (DP)
`(ADDED MDL LINK). (Entered: 05/31/2019)
`36 CERTIFICATE OF SERVICE re: pldg. ( 17 in MDL No. 2902, 7 in DE/1:19-cv-00310, 9
`in DE/1:19-cv-00347) Filed by Defendant Sandoz Inc. -- Associated Cases: MDL No.
`2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00312, DE/1:19-cv-00313,
`DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-
`cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872 (Gattuso, Dominick) Modified on
`6/3/2019 (DP)(ADDED MDL LINK). (Entered: 05/31/2019)
`37 CERTIFICATE OF SERVICE re: pldg. ( 16 in MDL No. 2902, 6 in DE/1:19-cv-00872)
`Filed by Defendant Teva Pharmaceutical Industries Ltd. -- Associated Cases: MDL No.
`2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00313, DE/1:19-cv-00314,
`DE/1:19-cv-00316, DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-
`
`https://ecf.jpml.uscourts.gov/cgi-bin/DktRpt.pl?46647738864669-L_1_0-1
`
`5/9
`
`Merck Sharp & Dohme Corp. Exhibit 2021
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040 Page 5
`
`

`

`4/13/2020
`
`06/04/2019
`
`06/04/2019
`
`06/06/2019
`
`06/06/2019
`
`06/13/2019
`
`06/14/2019
`
`CM/ECF for JPML (LIVE)
`cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872 (Gattuso, Dominick) Modified on
`6/3/2019 (DP)(ADDED MDL LINK). (Entered: 05/31/2019)
`38 NOTICE OF APPEARANCE re: pldg.( 1 in MDL No. 2902) Filed by John C Phillips on
`behalf of Defendants Apotex Corp., Apotex Inc. (Attachments: # 1 Proof of Service)
`Associated Cases: MDL No. 2902, DE/1:19-cv-00313 (Phillips, John) (Entered:
`06/04/2019)
`39 CORPORATE DISCLOSURE STATEMENT re: pldg. ( 1 in MDL No. 2902) --
`Identifying Corporate Parent Apotex Pharmaceuticals Holdings Inc. for Apotex Inc.;
`Corporate Parent APOTEX HOLDINGS, INC. for Apotex Corp.. (Attachments: # 1
`Proof of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00313 (Phillips, John)
`(Entered: 06/04/2019)
`40 RESPONSE -- (re: pldg. ( 1 in MDL No. 2902) ) Filed by Defendants Sandoz Inc., et al.
`(Attachments: # 1 Certificate of Service)
`
`Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-
`00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317,
`DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-
`cv-00347, DE/1:19-cv-00872 (Klein, Charles) Modified on 6/6/2019 (DP)(REMOVED
`DUPLICATE PARTY NAMES). (Entered: 06/06/2019)
`41 RESPONSE -- (re: pldg. ( 1 in MDL No. 2902) ) Filed by Defendants Mylan Inc., Mylan
`Pharmaceuticals Inc. (Attachments: # 1 Proof of Service)
`
`Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-
`00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317,
`DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-
`cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (Copland, Gordon) (Entered:
`06/06/2019)
`42 REPLY TO RESPONSE TO MOTION FOR TRANSFER re: pldg. (17 in DE/1:19-cv-
`00310, 18 in DE/1:19-cv-00311, 9 in DE/1:19-cv-00312, 17 in DE/1:19-cv-00313, 18 in
`DE/1:19-cv-00314, 17 in DE/1:19-cv-00316, 9 in DE/1:19-cv-00317, 9 in DE/1:19-cv-
`00318, 18 in DE/1:19-cv-00319, 16 in DE/1:19-cv-00320, 17 in DE/1:19-cv-00321, 17 in
`DE/1:19-cv-00347, 17 in DE/1:19-cv-00872, 41 in MDL No. 2902, 12 in WVN/1:19-cv-
`00101), (16 in DE/1:19-cv-00310, 17 in DE/1:19-cv-00311, 8 in DE/1:19-cv-00312, 16 in
`DE/1:19-cv-00313, 17 in DE/1:19-cv-00314, 16 in DE/1:19-cv-00316, 8 in DE/1:19-cv-
`00317, 8 in DE/1:19-cv-00318, 17 in DE/1:19-cv-00319, 15 in DE/1:19-cv-00320, 16 in
`DE/1:19-cv-00321, 16 in DE/1:19-cv-00347, 16 in DE/1:19-cv-00872, 40 in MDL No.
`2902), ( 1 in MDL No. 2902) Filed by Plaintiff Merck Sharp & Dohme Corp.
`(Attachments: # 1 Proof of Service)
`
`Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-
`00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317,
`DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-
`cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (Sheh, Anthony) (Entered:
`06/13/2019)
`43 MINUTE ORDER CLOSING BRIEFING re: pldg. ( 1 in MDL No. 2902)
`
`Briefing in this matter is now closed. The parties to actions on the motion(s) remain under
`a duty, pursuant to Panel Rules 6.1(f) and 6.2(d), to notify the Clerk of the Panel promptly
`of potential tag-along actions, as well as any development that moots the motion or fully
`disposes of any action on the motion. Parties in any potential tag-along action may file an
`Interested Party response, but must do so promptly, and in any event, no later than the
`https://ecf.jpml.uscourts.gov/cgi-bin/DktRpt.pl?46647738864669-L_1_0-1
`
`6/9
`
`Merck Sharp & Dohme Corp. Exhibit 2021
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040 Page 6
`
`

`

`4/13/2020
`
`CM/ECF for JPML (LIVE)
`Thursday prior to the hearing session at which the motion for transfer is to be heard by the
`Panel.
`
`Signed by Clerk of the Panel John W. Nichols on 6/14/2019.
`
`Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-
`00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317,
`DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-
`cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (DP) (Entered: 06/14/2019)
`44 HEARING ORDER re: pldg. ( 1 in MDL No. 2902) - SECTION A (DESIGNATED FOR
`ORAL ARGUMENT)
`
`PANEL HEARING set for 7/25/2019 in Portland, Oregon. Notices of Presentation or
`Waiver of Oral Argument due on or before 7/8/2019.
`
`Notice of Presentation or Waiver of Oral Argument form (JPML form 9) can be
`downloaded from our website.
`
`Signed by Judge Sarah S. Vance, Chair, PANEL ON MULTIDISTRICT LITIGATION, on
`6/18/2019.
`
`(Attachments: # 1 Courthouse Advisory)
`
`Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-
`00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317,
`DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-
`cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (RH) (Entered: 06/18/2019)
`45 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (20 in DE/1:19-cv-00310, 21 in
`DE/1:19-cv-00311, 12 in DE/1:19-cv-00312, 20 in DE/1:19-cv-00313, 21 in DE/1:19-cv-
`00314, 20 in DE/1:19-cv-00316, 12 in DE/1:19-cv-00317, 12 in DE/1:19-cv-00318, 21 in
`DE/1:19-cv-00319, 19 in DE/1:19-cv-00320, 20 in DE/1:19-cv-00321, 20 in DE/1:19-cv-
`00347, 20 in DE/1:19-cv-00872, 44 in MDL No. 2902, 15 in WVN/1:19-cv-00101) Filed
`by Gordon H. Copland on behalf of Defendants Mylan Inc., Mylan Pharmaceuticals Inc.
`(Attachments: # 1 Proof of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00310,
`DE/1:19-cv-00311, DE/1:19-cv-00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-
`cv-00316, DE/1:19-cv-00317, DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320,
`DE/1:19-cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101
`(Copland, Gordon) (Entered: 07/03/2019)
`46 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (20 in DE/1:19-cv-00310, 21 in
`DE/1:19-cv-00311, 12 in DE/1:19-cv-00312, 20 in DE/1:19-cv-00313, 21 in DE/1:19-cv-
`00314, 20 in DE/1:19-cv-00316, 12 in DE/1:19-cv-00317, 12 in DE/1:19-cv-00318, 21 in
`DE/1:19-cv-00319, 19 in DE/1:19-cv-00320, 20 in DE/1:19-cv-00321, 20 in DE/1:19-cv-
`00347, 20 in DE/1:19-cv-00872, 44 in MDL No. 2902, 15 in WVN/1:19-cv-00101) Filed
`by John C Phillips on behalf of Defendants Apotex Corp., Apotex Inc. (Attachments: # 1
`Certificate of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-
`00311, DE/1:19-cv-00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316,
`DE/1:19-cv-00317, DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-
`cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (Phillips, John)
`(Entered: 07/08/2019)
`47 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (20 in DE/1:19-cv-00310, 21 in
`DE/1:19-cv-00311, 12 in DE/1:19-cv-00312, 20 in DE/1:19-cv-00313, 21 in DE/1:19-cv-
`00314, 20 in DE/1:19-cv-00316, 12 in DE/1:19-cv-00317, 12 in DE/1:19-cv-00318, 21 in
`
`06/18/2019
`
`07/03/2019
`
`07/08/2019
`
`07/08/2019
`
`https://ecf.jpml.uscourts.gov/cgi-bin/DktRpt.pl?46647738864669-L_1_0-1
`
`7/9
`
`Merck Sharp & Dohme Corp. Exhibit 2021
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040 Page 7
`
`

`

`4/13/2020
`
`07/08/2019
`
`07/08/2019
`
`07/08/2019
`
`07/08/2019
`
`07/09/2019
`
`07/09/2019
`
`CM/ECF for JPML (LIVE)
`DE/1:19-cv-00319, 19 in DE/1:19-cv-00320, 20 in DE/1:19-cv-00321, 20 in DE/1:19-cv-
`00347, 20 in DE/1:19-cv-00872, 44 in MDL No. 2902, 15 in WVN/1:19-cv-00101) Filed
`by Charles B Klein on behalf of Defendants Sun Pharma Global FZE, et al. Associated
`Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00312,
`DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317, DE/1:19-
`cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-cv-00347,
`DE/1:19-cv-00872, WVN/1:19-cv-00101 (Klein, Charles) (Entered: 07/08/2019)
`48 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (20 in DE/1:19-cv-00310, 21 in
`DE/1:19-cv-00311, 12 in DE/1:19-cv-00312, 20 in DE/1:19-cv-00313, 21 in DE/1:19-cv-
`00314, 20 in DE/1:19-cv-00316, 12 in DE/1:19-cv-00317, 12 in DE/1:19-cv-00318, 21 in
`DE/1:19-cv-00319, 19 in DE/1:19-cv-00320, 20 in DE/1:19-cv-00321, 20 in DE/1:19-cv-
`00347, 20 in DE/1:19-cv-00872, 44 in MDL No. 2902, 15 in WVN/1:19-cv-00101) Filed
`by Anthony H. Sheh on behalf of Plaintiff Merck Sharp & Dohme Corp.
`
`Parties will WAIVE ORAL ARGUMENT IF ALL OTHER PARTIES IN THIS MATTER
`WAIVE ORAL ARGUMENT; otherwise the designated attorney shall present oral
`argument at the Panel hearing session.
`
`(Attachments: # 1 Exhibit 1, # 2 Proof of Service) Associated Cases: MDL No. 2902,
`DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-00312, DE/1:19-cv-00313, DE/1:19-
`cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317, DE/1:19-cv-00318, DE/1:19-cv-00319,
`DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-cv-00347, DE/1:19-cv-00872,
`WVN/1:19-cv-00101 (Sheh, Anthony) (Entered: 07/08/2019)
`49 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (21 in DE/1:19-cv-00311, 20 in
`DE/1:19-cv-00321, 44 in MDL No. 2902) Filed by David H. Silverstein on behalf of
`Defendants Anchen Pharmaceuticals, Inc., Par Pharmaceuticals, Inc., Wockhardt Bio AG,
`Wockhardt USA LLC (Attachments: # 1 Schedule of Actions, # 2 Proof of Service)
`Associated Cases: MDL No. 2902, DE/1:19-cv-00311, DE/1:19-cv-00321 (Silverstein,
`David) DELETED DUPLICATE PARTIES NAMES Modified on 7/9/2019 (RH).
`(Entered: 07/08/2019)
`50 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (20 in DE/1:19-cv-00316, 19 in
`DE/1:19-cv-00320, 20 in DE/1:19-cv-00872, 44 in MDL No. 2902) Filed by Neal Seth on
`behalf of Defendants Torrent Pharma Inc., et al. (Attachments: # 1 Exhibit Attachment A,
`# 2 Exhibit Attachment B, # 3 Proof of Service Proof of Service) Associated Cases: MDL
`No. 2902, DE/1:19-cv-00316, DE/1:19-cv-00320, DE/1:19-cv-00872 (Seth, Neal)
`DELETED DUPLICATE PARTIES NAMES Modified on 7/9/2019 (RH). (Entered:
`07/08/2019)
`51 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (20 in DE/1:19-cv-00310, 44 in
`MDL No. 2902) Filed by Matthew J. Becker on behalf of Defendants Alvogen Malta
`Operations Ltd., Alvogen Pine Brook LLC (Attachments: # 1 Proof of Service) Associated
`Cases: MDL No. 2902, DE/1:19-cv-00310 (Becker, Matthew) (Entered: 07/08/2019)
`52 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (12 in DE/1:19-cv-00312, 12 in
`DE/1:19-cv-00317, 12 in DE/1:19-cv-00318, 44 in MDL No. 2902) Filed by Dominick
`Gattuso on behalf of Defendants Sandoz Inc., et al. (Attachments: # 1 Exhibit Certificate
`of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00312, DE/1:19-cv-00317,
`DE/1:19-cv-00318 (Gattuso, Dominick) (Entered: 07/09/2019)
`53 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (12 in DE/1:19-cv-00312, 12 in
`DE/1:19-cv-00317, 12 in DE/1:19-cv-00318, 44 in MDL No. 2902) Filed by Dominick
`Gattuso on behalf of Defendants Sandoz Inc., et al. (Attachments: # 1 Exhibit Certificate
`
`https://ecf.jpml.uscourts.gov/cgi-bin/DktRpt.pl?46647738864669-L_1_0-1
`
`8/9
`
`Merck Sharp & Dohme Corp. Exhibit 2021
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040 Page 8
`
`

`

`4/13/2020
`
`07/09/2019
`
`08/08/2019
`
`CM/ECF for JPML (LIVE)
`of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00312, DE/1:19-cv-00317,
`DE/1:19-cv-00318 (Gattuso, Dominick) (Entered: 07/09/2019)
`54 NOTICE OF WAIVER OF ORAL ARGUMENT re: pldg. (12 in DE/1:19-cv-00312, 12 in
`DE/1:19-cv-00317, 12 in DE/1:19-cv-00318, 44 in MDL No. 2902) Filed by Dominick
`Gattuso on behalf of Defendants Sandoz Inc., et al. (Attachments: # 1 Exhibit Certificate
`of Service) Associated Cases: MDL No. 2902, DE/1:19-cv-00312, DE/1:19-cv-00317,
`DE/1:19-cv-00318 (Gattuso, Dominick) (Entered: 07/09/2019)
`55 CONSENT ORDER re: pldg(s). 1 Consenting to transfer of litigation to Judge Richard G.
`Andrews in the Delaware District Court for coordinated or consolidated pretrial
`proceedings.
`
`Signed by Chief Judge, USDC Leonard P. Stark on 8/7/19.
`
`08/08/2019
`
`(SM) (Entered: 08/08/2019)
`56 TRANSFER ORDER re: pldg. ( 1 in MDL No. 2902) Transferring 1 action(s) to Judge
`Richard G Andrews in the D. Delaware.
`
`Signed by Judge Sarah S. Vance, Chair, PANEL ON MULTIDISTRICT LITIGATION, on
`8/8/2019.
`
`Associated Cases: MDL No. 2902, DE/1:19-cv-00310, DE/1:19-cv-00311, DE/1:19-cv-
`00312, DE/1:19-cv-00313, DE/1:19-cv-00314, DE/1:19-cv-00316, DE/1:19-cv-00317,
`DE/1:19-cv-00318, DE/1:19-cv-00319, DE/1:19-cv-00320, DE/1:19-cv-00321, DE/1:19-
`cv-00347, DE/1:19-cv-00872, WVN/1:19-cv-00101 (SM) (Entered: 08/08/2019)
` XYZ CASES ENTERED -- 1 related action(s) originating in the transferee district. JPML
`notified on 1/27/20 via e-mail. --
`
`Delaware District Court (1:19-cv-02192) (DP) (Entered: 02/04/2020)
`
`02/04/2020
`
`PACER Service Center
`Transaction Receipt
`04/13/2020 17:08:07
`PACER Login: wc0010:2660228:0 Client Code:
`26197.0146
`Description:
`Search Criteria: MDL No. 2902
`Docket Report
`Billable Pages: 8
`Cost:
`0.80
`
`https://ecf.jpml.uscourts.gov/cgi-bin/DktRpt.pl?46647738864669-L_1_0-1
`
`9/9
`
`Merck Sharp & Dohme Corp. Exhibit 2021
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040 Page 9
`
`